Table 1.
Expression of Rho GTPase activating protein 12 in different groups based on clinical pathological features
|
Clinicopathological features
|
ARHGAP12 protein expression
|
t (t-test) or F (ANOVA)
|
P value
|
||
|
Number
|
mean
|
SD
|
|||
| Age | 1.6400 | 0.1017 | |||
| > 60 | 101 | 5.743 | 3.504 | ||
| ≤ 60 | 303 | 6.342 | 3.065 | ||
| Gender | 2.1130 | 0.0352 | |||
| Male | 339 | 6.046 | 3.172 | ||
| Female | 65 | 6.954 | 3.179 | ||
| Pathology grade | 1.4470 | 0.2366 | |||
| Grade I-II | 203 | 6.043 | 3.347 | ||
| Grade II-III | 85 | 5.995 | 3.099 | ||
| Grade III-IV | 113 | 6.630 | 2.960 | ||
| Tumor necrosis | 1.5980 | 0.1112 | |||
| Yes | 178 | 6.279 | 2.931 | ||
| No | 80 | 5.570 | 3.989 | ||
| Satellite nodule | 0.7686 | 0.2944 | |||
| Yes | 81 | 6.079 | 3.145 | ||
| No | 287 | 6.199 | 3.275 | ||
| Vascular invasion | 4.9580 | 0.0075 | |||
| M0 | 199 | 5.733 | 3.048 | ||
| M1 | 142 | 6.501 | 3.217 | ||
| M2 | 58 | 7.062 | 3.438 | ||
| TNM stages | |||||
| T | 5.1990 | 0.0072 | |||
| T1 | 45 | 4.631 | 3.734 | ||
| T2 | 44 | 7.063 | 3.982 | ||
| T3 | 9 | 4.000 | 4.000 | ||
| N | 2.1830 | 0.0315 | |||
| N0 | 96 | 5.563 | 4.016 | ||
| N1 | 3 | 10.670 | 2.309 | ||
| M | 1.5650 | 0.1208 | |||
| M0 | 98 | 5.653 | 4.035 | ||
| M1 | 1 | 12.000 | 0.000 | ||
| HBV | 0.3460 | 0.7296 | |||
| HBV-positive | 182 | 6.332 | 3.626 | ||
| HBV-negative | 62 | 6.155 | 3.002 | ||
Microvascular invasion grading: M0 level: Microvascular invasion not found; M1 grade: ≤ 5 microvascular invasions and occur in the area of proximal adjacent liver tissue (≤ 1 cm); M2 grade: > 5 microvascular invasions, or microvascular invasions that occur in the area of liver tissue distally adjacent to the cancer (> 1 cm). ARHGAP12: Rho GTPase activating protein 12; TNM: Tumor-node-metastasis; HBV: Hepatitis B virus.